Rapamycin for Women: Fertility, Menopause, and the Evidence on Women's Healthspan
Two of the most consequential rapamycin studies of the past two years were conducted exclusively in women: the Columbia VIBRANT trial in women approaching perimenopause, and the 2025 IVF trial in women with prior failed cycles. Both showed measurable benefit; both reframe how the drug should be thought about in women's health.
For women undergoing IVF with prior failures, low-dose rapamycin (1 mg daily for 21–28 days during follicular development) more than doubled clinical pregnancy rates—50% vs 28%—and tripled them in day 5–6 blastocyst transfers (27.5% vs 7.7%).
In the VIBRANT pilot, 5 mg weekly rapamycin for 12 weeks in women aged 35–45 slowed ovarian follicle loss by approximately 20% and was well-tolerated, with participants reporting improvements in energy, memory, skin, and hair quality.
The PEARL longevity trial detected one of its most striking findings exclusively in women: those receiving 10 mg weekly rapamycin showed approximately 6% greater lean body mass at 48 weeks. The same signal was not seen in men.
Beyond reproductive aging, rapamycin is being studied in women for cardiovascular protection during the menopause transition, bone health, skin and hair changes, autoimmune conditions (which disproportionately affect women), and overall healthspan.
Rapamycin is contraindicated during pregnancy, breastfeeding, and active conception attempts outside of physician-supervised IVF protocols. The drug's effects can be sex-specific, and dosing decisions should account for body composition, hormonal context, and reproductive intent.
Why Rapamycin Is Specifically Interesting for Women
Most of the foundational research on rapamycin and aging—the mouse lifespan trials, the immune function studies, the cardiovascular data—was conducted in mixed-sex or predominantly male cohorts. Until recently, very little was known about whether the drug behaves differently in women or addresses biological processes that matter more in women than in men.
That has changed quickly. Three converging lines of evidence have moved women specifically to the center of rapamycin research:
First, ovarian aging is a process that runs ahead of other aging processes. Women lose reproductive function on a faster timeline than they lose cardiovascular, immune, or musculoskeletal function. The ovary effectively ages two to three decades earlier than the rest of the body, with measurable decline beginning in the mid-30s and reaching functional cessation at menopause around age 51 [1]. Because the mTOR pathway sits upstream of this decline, rapamycin offers a rare pharmacological lever on a tissue where aging is both early and consequential.
Second, the loss of ovarian hormones at menopause is not just about reproduction. Estrogen and progesterone influence cardiovascular function, bone density, skin and hair biology, cognitive function, and metabolic regulation. When ovarian function declines, women experience accelerated changes in many of these systems simultaneously. Anything that meaningfully extends ovarian function has cascading effects beyond fertility.
Third, several recent findings have surfaced sex-specific responses to rapamycin. In the PEARL trial, the lean-body-mass benefit was observed in women, not men [2]. Several animal studies have shown sex-differentiated lifespan effects. The biology of how the drug interacts with female physiology is increasingly understood as a distinct research area, not a footnote.
For these reasons, women are not "incidentally" served by the broader rapamycin literature. Several of the most rigorous human studies completed in 2024 and 2025 were designed specifically to answer questions about female biology.
Rapamycin for Ovarian Aging and Fertility
This is where the human evidence is strongest, most recent, and most consequential.
The 2025 IVF Trial
Published in Cell Reports Medicine in late 2025, this randomized clinical trial enrolled 100 women (average age 36) with at least one prior failed IVF cycle. Participants received 1 mg of oral rapamycin daily for 3–4 weeks during the ovarian stimulation phase before egg retrieval [1].
The results were striking:
- More high-quality embryos. Women in the rapamycin group produced significantly more zygotes (fertilized eggs) and more embryos that progressed through normal cell division.
- Better blastocyst development. A higher proportion of embryos reached the day 5–6 blastocyst stage—the milestone most strongly correlated with successful implantation.
- Higher clinical pregnancy rates. Overall, clinical pregnancy reached 50% in the rapamycin group versus 28% in controls. Among women undergoing day 5–6 blastocyst transfer, rates were 27.5% vs 7.7%—more than a threefold increase.
- No reduction in live birth rates.
The biological mechanism was made explicit by the same study. Multi-omics analysis showed that aging cumulus cells (the support cells surrounding the egg) develop a characteristic pattern of excessive protein synthesis, reduced autophagy, and accumulation of misfolded proteins—what the authors called "ribosome dysregulation." Short-term mTOR inhibition appeared to correct this imbalance during the critical follicular window.
For a complete analysis of this trial including the mechanistic findings, see our detailed review of the IVF trial.
The VIBRANT Trial (Columbia)
Running in parallel, Columbia University's VIBRANT trial (Validating Benefits of Rapamycin for Reproductive Aging Treatment) is testing whether weekly rapamycin can delay ovarian aging in women not undergoing IVF. The pilot enrolled women aged 35–45 in late stage 3a reproductive aging—just before perimenopause onset—and randomized them to 5 mg rapamycin or placebo once weekly for 12 weeks.
Early results reported in 2024 indicated that rapamycin slowed the rate of follicle loss by approximately 20%. While women typically lose around 50 eggs per month through natural follicular atresia, rapamycin-treated participants lost closer to 15 per month [3].
Participants also reported improvements in general health, memory, energy, and skin and hair quality—findings consistent with the broader rapamycin literature in non-female-specific populations.
The trial is now expanding toward a target enrollment of over 1,000 women. Mature results are anticipated within the next two years.
What These Trials Together Suggest
The two studies address different questions. The IVF trial asks whether short-term, targeted mTOR inhibition can improve egg quality during a defined fertility intervention. VIBRANT asks whether longer-term weekly dosing can extend ovarian lifespan in women who are not actively trying to conceive.
Both have produced positive early signals. Together they reframe the conversation: ovarian aging is not solely a count problem (how many eggs remain) but also a quality problem (how well those eggs and their surrounding cells function). Rapamycin appears to influence the quality dimension.
For a deeper treatment of how rapamycin engages ovarian biology, including the underlying mechanisms and earlier preclinical work, see our foundational article on rapamycin, ovarian health, and fertility.
Rapamycin and Perimenopause / Menopause
The menopause transition is not a single event. It begins as early as the mid-30s with subtle decline in ovarian function, accelerates through the perimenopausal years (typically late 40s), and reaches the post-menopausal state around age 51 on average. Across this 15–20 year window, women experience an increasingly broad set of changes driven by declining ovarian hormone production: hot flashes and sleep disruption, cognitive and mood changes, skin and hair changes, accelerated bone loss, shifts in body composition, and increasing cardiovascular risk.
Rapamycin does not replace estrogen. It does not act on the ovary the way menopausal hormone therapy does. What it appears to do is engage the underlying biological aging process that drives ovarian decline in the first place.
The implications for women in midlife are several:
Extended ovarian function may extend hormonal protection. Estrogen and progesterone produced by the ovary have effects on cardiovascular tissue, bone, brain, and skin. If rapamycin extends the functional lifespan of the ovary, it may indirectly preserve some of these downstream benefits without requiring exogenous hormone administration. This remains a hypothesis—the trials haven't run long enough to confirm it—but it is the strongest mechanistic argument for rapamycin in perimenopausal women.
Quality-of-life signals are consistent across studies. Self-reported improvements in energy, sleep, memory, skin, and hair quality appear in both the VIBRANT pilot and the larger PEARL trial. These are soft endpoints, but they are remarkably consistent.
Rapamycin and hormone therapy are not mutually exclusive. No trial has directly studied combined use, and combinations need physician oversight, but there is no mechanistic reason rapamycin and hormone therapy would conflict. They act on entirely different pathways.
Other Areas Where Rapamycin May Matter More for Women Than Men
Lean Body Mass
The PEARL trial detected one of its most striking findings in women specifically. After 48 weeks of 10 mg weekly rapamycin, women in the higher-dose arm showed approximately 6% greater lean body mass compared with baseline [2]. The signal was not seen in men or at the lower dose.
This is biologically counterintuitive. mTOR is classically required for muscle protein synthesis, and one might expect an mTOR inhibitor to cause muscle loss. The likely explanation is that aging muscle develops anabolic resistance—it becomes less responsive to growth signals from amino acids and resistance training due to chronic mTOR overactivation. Periodic relief from that pressure may restore sensitivity. Why this effect appears stronger in women is not yet established, but it intersects meaningfully with the accelerated sarcopenia that often accompanies the menopause transition.
Autoimmune Conditions
Autoimmune disease occurs roughly 2–3 times more often in women than in men. Rapamycin's effects on the immune system at low intermittent doses are not classically immunosuppressive—they appear to restore immune balance rather than suppress it—and there is preclinical and early clinical interest in its use for several autoimmune conditions including lupus and Sjögren's syndrome.
This is an active research area. Definitive guidance for autoimmune use of rapamycin is not yet established, but for women with diagnosed autoimmune conditions considering rapamycin, the conversation with a prescribing clinician is meaningfully different than for the general population. We've covered the relevant immune-system mechanisms in detail.
Skin and Hair
Topical rapamycin has been studied for skin aging in both sexes, with measurable improvements in markers of cellular senescence and visible texture in older skin. Hair follicle biology also intersects with mTOR signaling, and there is emerging interest in rapamycin for certain forms of hair loss including female pattern hair loss and frontal fibrosing alopecia.
Healthspan offers compounded topical rapamycin for skin and topical rapamycin for hair for women interested in these specific applications.
Bone Health
Postmenopausal bone loss is one of the most consequential downstream effects of ovarian aging. mTOR signaling participates in bone turnover, and several preclinical studies have suggested that intermittent rapamycin may improve bone quality in aged animals. Human evidence specific to bone is still limited, but if rapamycin extends ovarian estrogen production, indirect bone benefits would be expected.
For a focused treatment of the menopause biology and how mTOR inhibition may engage it, see our review on rapamycin and menopausal symptoms.
How Women Typically Use Rapamycin for Healthspan
The dosing regimens used in longevity-focused women's protocols generally fall in the same range as the general population, with a few practical considerations:
Use Case: Typical Regimen
General healthspan (premenopausal): 3–10 mg once weekly
General healthspan (postmenopausal): 3–10 mg once weekly
IVF support (under specialist oversight): 1 mg daily × 3–4 weeks during follicular phase
Ovarian aging delay (under specialist oversight): 5 mg weekly (per VIBRANT protocol)
Weight-adjusted dosing follows the same 0.075–0.15 mg/kg weekly range used in mixed-sex protocols. For most adult women, this corresponds to roughly 4–10 mg weekly.
Key practical considerations specific to women:
- Reproductive status matters enormously. Rapamycin should not be taken during pregnancy, breastfeeding, or active conception attempts outside of a physician-supervised IVF protocol. Women planning conception in the near term need a clear washout period before attempting to conceive, the timing of which should be determined with a prescribing clinician.
- Body composition can affect dosing. Women on average have higher body fat percentage than men of the same body weight. Rapamycin is lipophilic and sequesters in adipose tissue, which can produce different circulating drug levels for the same milligram dose. Lab monitoring helps individualize dosing.
- Hormonal context matters. For women on menopausal hormone therapy, oral contraceptives, or other medications that interact with the CYP3A4 pathway, dose adjustment and interaction screening are essential.
- Cycle timing in premenopausal women. Some clinicians prefer to time weekly rapamycin doses consistently within the menstrual cycle. Current evidence does not establish a single optimal timing, but consistency is reasonable.
For a complete treatment of dosing principles including the full evidence base, see our comprehensive rapamycin dosage guide and our in-depth review of dosing for longevity.
Side Effects and Safety in Women
The side effect profile at low weekly doses appears similar to that observed in men, with a few considerations specific to female biology:
Most commonly reported:
- Mouth sores or canker sores (most common across both sexes)
- Mild gastrointestinal symptoms
- Transient headache or insomnia early in treatment
- Mild lipid elevations in a subset of users
Less common but worth noting in women specifically:
- Menstrual cycle changes have been reported in some women on weekly rapamycin, including occasional cycle irregularity or mild flow changes. These are generally transient. Women experiencing significant menstrual changes should discuss them with their prescriber.
- No consistent signal of reduced fertility has emerged at low weekly doses in women not actively trying to conceive. The IVF trial in fact showed improved fertility outcomes with daily dosing during the stimulation window.
Contraindications for women:
- Pregnancy or active conception attempts outside of IVF protocols
- Breastfeeding
- Active infection
- Significantly compromised immune function
- Uncontrolled metabolic disease
- Use of medications with major CYP3A4 interactions that cannot be managed
Frequently Asked Questions
Can women take rapamycin?
Yes. There is no evidence-based reason to exclude women from low-dose rapamycin protocols, outside of pregnancy, breastfeeding, and active conception attempts. Two of the most rigorous human rapamycin trials of the past two years were conducted exclusively in women, both with positive results.
Is rapamycin safe for women?
At low weekly doses (3–10 mg), the safety profile in women appears similar to that observed in men, with a few female-specific considerations around menstrual cycle effects, hormonal context, and reproductive intent. Long-term safety data through one year (PEARL trial) and observational data from hundreds of women using rapamycin off-label have not surfaced major safety signals when the drug is used under physician supervision.
Does rapamycin delay menopause?
Early evidence from the Columbia VIBRANT trial suggests that weekly rapamycin can slow the rate of ovarian follicle loss by approximately 20%, which would translate to delayed menopause if the effect is sustained over years. Definitive evidence requires the larger ongoing trial to complete. The mechanism is biologically plausible and is now supported by multiple lines of evidence.
Can rapamycin help with perimenopause symptoms?
This has not been directly studied in a randomized trial. However, women in both the VIBRANT and PEARL trials reported improvements in energy, sleep, memory, and skin and hair quality—several of which overlap with perimenopausal complaints. Whether rapamycin specifically addresses hot flashes, mood changes, or vasomotor symptoms is not yet established.
Should I take rapamycin if I'm trying to get pregnant?
No—not outside of a physician-supervised IVF protocol. Rapamycin can affect ovulation timing and embryonic development. The IVF trial that showed positive results used a tightly defined window (1 mg daily for 3–4 weeks during follicular development before egg retrieval) under specialist oversight. Women planning natural conception should discontinue rapamycin and observe an appropriate washout period before attempting to conceive.
Can rapamycin be taken during pregnancy?
No. Rapamycin is contraindicated during pregnancy. It is FDA Pregnancy Category C and carries clear potential for fetal harm. Women who become pregnant while taking rapamycin should stop the drug immediately and notify their prescriber.
Can rapamycin be taken while breastfeeding?
No. Rapamycin is not recommended during breastfeeding. The drug is excreted in breast milk in studies of nursing animals, and human safety data in this setting is insufficient.
Will rapamycin affect my menstrual cycle?
Some women report mild cycle irregularity or flow changes, particularly early in treatment. These are generally transient. Significant or persistent menstrual changes should be discussed with the prescribing clinician.
Does rapamycin help with hot flashes?
There is no direct trial evidence that rapamycin reduces hot flashes. The drug does not act on hormonal pathways the way menopausal hormone therapy does. Some women report symptom improvements, but these have not been tested against placebo in a hot-flash-specific trial.
Is rapamycin better than HRT for menopause?
The two work through entirely different mechanisms and are not directly comparable. Menopausal hormone therapy replaces declining estrogen and progesterone and is the most effective treatment for vasomotor symptoms. Rapamycin acts on an aging pathway upstream of ovarian decline and may extend ovarian function itself. They are not mutually exclusive, and decisions about either should involve a clinician familiar with both.
What's the best dose of rapamycin for women?
Most longevity protocols start at 3–5 mg once weekly and may titrate to 5–10 mg weekly based on body weight, tolerability, and lab response. Specific dosing in IVF or ovarian-aging protocols is different and is determined by the specialist managing that intervention. Body weight, body composition, and any concurrent medications all affect the appropriate dose.
Can I take rapamycin if I'm on hormone replacement therapy?
There is no mechanistic conflict between rapamycin and hormone therapy—they act on different pathways. Combined use has not been studied in trials, however, so it should be done under physician oversight. The prescriber should review concurrent medications for any CYP3A4 interactions.
Does rapamycin help with female hair loss?
Topical rapamycin has emerging interest for several hair conditions including female pattern hair loss. The evidence is preliminary. Healthspan offers topical formulations for this specific application.
Does rapamycin help skin aging in women?
Topical rapamycin has been studied for skin aging in both sexes with measurable improvements in cellular senescence markers and visible texture in older skin. Healthspan offers topical formulations.
How Healthspan Approaches Rapamycin for Women
The Healthspan Women's Health Program provides physician-supervised access to rapamycin alongside lab monitoring and individualized protocol design. The Rapamycin Protocol itself is the same underlying treatment; what differs in the women's health context is the addition of reproductive and hormonal considerations in baseline workup, dosing decisions, and monitoring.
For women specifically interested in:
- Fertility extension or IVF support: This requires reproductive endocrinology specialist involvement and should be coordinated with the IVF center managing the cycle.
- Perimenopausal symptom management or ovarian aging delay: Suitable for the standard Rapamycin Protocol with women's-health-focused monitoring.
- General healthspan and longevity: Same protocol as the broader population, with female-specific lab and dosing considerations.
- Skin or hair applications: Topical formulations deliver local effect without significant systemic exposure.
For users on compounded preparations, the Rapamycin Bioavailability Panel quantifies circulating drug levels and informs dose adjustment.
Conclusion: Where the Evidence Stands
Two years ago, "rapamycin for women" was largely an extrapolation from mixed-sex animal and human research. That is no longer the case. The IVF trial published in late 2025 produced the cleanest demonstration to date that short-term mTOR inhibition can functionally improve a reproductive-aging endpoint in humans. The VIBRANT trial is producing parallel evidence in non-IVF settings. The PEARL trial detected a lean-mass benefit specifically in women. Across these studies, the women's-health-specific signal is real, internally consistent, and biologically explained.
Important gaps remain. None of these trials has run long enough to demonstrate hard outcomes like delayed menopause confirmed by years of follow-up, reduced cardiovascular events, or live-birth improvements at scale. The trials currently in progress should begin to fill these gaps over the next several years.
For women in their 30s, 40s, and 50s considering whether rapamycin is right for them, the question is no longer whether the drug has plausible benefits for female biology. The 2024–2025 evidence has answered that. The remaining question is one of fit: whether the individual's reproductive intent, hormonal context, baseline health, and longevity goals make low-dose weekly rapamycin a reasonable component of their healthspan strategy. That decision is appropriately made with a clinician who understands both the drug and the relevant aspects of women's health biology.
Related Research
- Li, J., et al. (2025). Ribosome dysregulation and intervention in age-related infertility. Cell Reports Medicine, 6(11), 102424. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00497-5
- Moel, M., et al. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging, 17(4), 908–936. https://doi.org/10.18632/aging.206235
- Columbia University Department of Obstetrics & Gynecology. (2024). Ground-breaking Clinical Trial Explores Delaying Menopause. 2024 Annual Report. https://reports.obgyn.columbia.edu/2024-annual-report/ground-breaking-clinical-trial-explores-delaying-menopause/
- Kaeberlein, T. L., et al. (2023). Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience, 45(5), 2757–2768. https://doi.org/10.1007/s11357-023-00818-1
- Mannick, J. B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179. https://doi.org/10.1126/scitranslmed.3009892
- Dou, X., et al. (2017). Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged female mice. Aging Cell, 16(4), 825–836. https://doi.org/10.1111/acel.12617
- Garcia, D. N., et al. (2019). Effect of caloric restriction and rapamycin on ovarian aging in mice. GeroScience, 41(4), 395–408. https://pubmed.ncbi.nlm.nih.gov/31359237/
Related studies